What Is Track and Trace in the Pharmaceutical Industry?

01Defining Pharmaceutical Track and Trace

Pharmaceutical track and trace is the operational and regulatory system that allows every individual medicine pack to be followed through its journey across the supply chain. The phrase contains two complementary verbs that describe distinct capabilities. Track refers to forward visibility, the ability to follow a pack as it moves from manufacturer to wholesaler to pharmacy to patient. Trace refers to backward visibility, the ability to start from a pack at any point in the chain and reconstruct where it has been.

Together, these two capabilities transform pharmaceutical supply chains from systems of trust into systems of verification. Before track and trace, the assumption was that a pack passing through licensed trading partners was legitimate. After track and trace, that assumption is replaced by continuous verification against authoritative data, with every legitimate pack carrying a digital fingerprint that distinguishes it from counterfeit or diverted product.

Academically, pharmaceutical track and trace represents the most mature implementation of what supply chain researchers broadly call item-level traceability. Comparable systems exist in medical devices (UDI), food and beverage (FSMA in the United States, similar elsewhere), and high-value consumer goods, but no industry has implemented item-level traceability with the breadth, depth, and regulatory rigor that pharmaceuticals have achieved.

Journalistically, pharmaceutical track and trace is the regulatory response to one of the most serious unattended public health threats of the modern era: counterfeit medicines. The World Health Organization estimates that approximately one in ten medical products in low and middle-income countries is substandard or falsified, contributing to an estimated one million deaths annually. Track and trace is the systemic infrastructure designed to make that figure decline.

02The Three Pillars: Serialization, Aggregation, and Event Exchange

Pharmaceutical track and trace is not a single technology but an integrated system built on three interdependent layers. Understanding the layers is essential because they are often confused, conflated, or partially implemented in ways that produce incomplete traceability.

The three layers must work together. A serialized pack without aggregation cannot be efficiently verified at the case level. An aggregated supply chain without event exchange produces only local visibility, not end-to-end traceability. Event exchange without underlying serialization and aggregation has no meaningful data to exchange. The completeness of pharmaceutical track and trace depends on all three layers operating coherently across the entire supply chain.

For a precise comparison of how these three concepts differ and relate, the dedicated serialization vs aggregation vs track and trace page is the authoritative reference.

03Why Track and Trace Exists: The Public Health Case

The regulatory case for pharmaceutical track and trace was built over two decades, driven by a sequence of incidents that exposed the inadequacy of batch-level controls in increasingly globalized supply chains.

The counterfeit medicine crisis

Documented counterfeit pharmaceutical incidents accelerated through the 2000s, including the 2003 Lipitor case in the United States, the 2007 to 2008 heparin contamination that killed at least 81 American patients after counterfeit active pharmaceutical ingredient entered legitimate finished product, and persistent counterfeit antimalarial circulation across sub-Saharan Africa documented by WHO. The detailed historical arc appears on the history of pharma traceability page.

The supply chain visibility problem

Globalized pharmaceutical supply chains, with active ingredients sourced from one continent, finished products manufactured on another, and patients located on a third, created visibility gaps that batch numbers could not close. Regulators concluded that item-level identification was the only architecture capable of providing the visibility modern supply chains require.

The diversion and reimbursement fraud problem

Beyond counterfeiting, serialized identifiers enable detection of pharmaceutical diversion (legitimate product moved through illegitimate channels), parallel imports, and reimbursement fraud. The economic value of these detection capabilities, while difficult to quantify precisely, runs into tens of billions of dollars annually.

The recall precision problem

Batch-level recalls typically affect tens of thousands of packs even when only a fraction are genuinely defective. Item-level traceability allows recalls to be targeted to exactly the affected population, reducing both operational cost and the disruption to legitimate inventory.

The convergence of these concerns produced the first wave of regulatory mandates between 2008 and 2013, beginning with Turkey's ITS in 2010 and expanding through the EU Falsified Medicines Directive (2011, enforced 2019) and the US Drug Supply Chain Security Act (2013, with phased enforcement through 2024). The dedicated anti-counterfeiting overview and drug supply chain security page cover the threats track and trace exists to address in greater depth.

04How Track and Trace Works: A Pack's Journey

The clearest way to understand pharmaceutical track and trace is to follow a single pack through its lifecycle. Consider a 100-pack case of antibiotics manufactured in Mumbai for distribution to a hospital pharmacy in Frankfurt.

Stage 1: Manufacturing and serialization

At the manufacturing site in Mumbai, the packaging line prints a unique 2D DataMatrix barcode on each carton, encoding the GTIN, serial number, batch number, and expiry date. A vision system verifies each printed code, rejecting any that fail to read correctly. Successfully verified codes are committed to the manufacturer's serialization repository as "commissioned" identifiers.

Stage 2: Aggregation

As packs are loaded into a case, each pack's code is scanned and the case is assigned its own Serial Shipping Container Code (SSCC) on a printed label. The serialization software records that this SSCC is the parent of the 100 child serial numbers. The case is then loaded onto a pallet, the pallet receives its own SSCC, and the case SSCCs are linked to the pallet SSCC.

Stage 3: Dispatch and shipping event

When the pallet leaves the manufacturing site, an EPCIS shipping event is generated. The event records what is being shipped (the pallet SSCC and all linked child identifiers), when it was shipped, who shipped it, and who is the intended recipient. The event is transmitted to the German wholesaler before the physical pallet arrives.

Stage 4: Receiving and verification

When the pallet arrives at the German wholesaler, the wholesaler scans the pallet SSCC and verifies the contents against the EPCIS shipping event. Any discrepancies, missing packs, unexpected packs, identifier mismatches, are flagged for investigation.

Stage 5: Sub-distribution

The wholesaler ships individual cases to hospital and retail pharmacy customers. Each case shipment generates a new EPCIS event, transferring custody and adding to the historical record.

Stage 6: Verification at dispense

When the hospital pharmacist dispenses a pack to a patient, the pack is scanned and verified against the European Medicines Verification System. The system confirms that the pack is legitimate, has not been previously dispensed, has not been recalled, and is not expired. The pack is then marked as dispensed and is no longer available for verification in subsequent transactions.

Stage 7: Historical traceability

If at any point the pack becomes the subject of investigation, the full historical event chain can be reconstructed from the EPCIS records held by each party in the chain (under DSCSA-style architectures) or from the central verification system (under FMD-style architectures).

This journey, with variations specific to each regulatory framework, plays out billions of times annually across pharmaceutical supply chains worldwide.

05The Global Regulatory Landscape at a Glance

More than 60 countries now operate pharmaceutical track and trace mandates, each with distinct technical, operational, and reporting requirements. The major frameworks fall into several architectural families.

Full chain track and trace

The United States operates the most demanding full chain framework under the Drug Supply Chain Security Act (DSCSA), requiring peer-to-peer transaction information exchange between every trading partner from manufacturer to dispenser.

End-point verification

The European Union operates under the Falsified Medicines Directive (FMD) with verification at the point of dispense rather than tracking each intermediate handoff. The European Medicines Verification System processes billions of verifications annually.

Comprehensive multi-tier verification

Russia's Chestny ZNAK, Saudi Arabia's SFDA RSD, and the UAE's Tatmeen require verification at multiple supply chain points including import, distribution, and dispense, generally with full aggregation requirements.

National variations

Major markets including India, China, Brazil, South Korea, Turkey, Japan, Australia, Canada, and dozens of others operate distinct national systems with substantial variation in technical specifications, reporting platforms, and enforcement timing.

The fragmentation creates substantial compliance complexity for multinational manufacturers. Our global regulations pillar page provides an integrated comparative view across all 60+ jurisdictions, with country-by-country detail in dedicated guides.

06The Technology Stack Behind Track and Trace

Pharmaceutical track and trace operates on a technology stack conventionally organized into five layers, often called L1 through L5.

The detailed treatment of this architecture appears on the serialization architecture page.

The standards layer underlying the technology stack is dominated by GS1, the global standards body that provides the identifiers (GTIN, SSCC), the symbology (GS1 DataMatrix), and the event exchange format (EPCIS) that make interoperable traceability possible. The GS1 pharma standards page provides a comprehensive overview.

Emerging technologies including blockchain, AI, IoT, and smart packaging are extending the capability of traceability systems beyond what serialization alone provides. The future of pharma traceability page explores these trajectories in depth.

07Stakeholders and Their Roles

Pharmaceutical track and trace requires coordination across an extended ecosystem of stakeholders, each with distinct responsibilities and operational requirements.

Manufacturers bear the largest share of implementation cost and operational burden. They are responsible for serializing every pack, maintaining aggregation hierarchies, generating EPCIS events, and reporting to regulatory repositories. The manufacturer page in Silo 6 covers their role in detail.

Contract manufacturers (CMOs and CDMOs) serialize on behalf of brand owners and must integrate their operations with multiple customer systems simultaneously. The CMO page addresses the specific complexities of contract manufacturing.

Wholesalers and distributors receive serialized and aggregated product, verify it against EPCIS records, and forward it to dispensers. Their role differs substantially between DSCSA, FMD, and other regulatory architectures. See the wholesaler page for details.

Retail and hospital pharmacies are the dispensing endpoint where verification against authoritative systems detects counterfeit or diverted product before it reaches patients. The pharmacy page and hospital page cover their specific obligations.

Repackagers must maintain aggregation integrity through repackaging operations, a particularly complex challenge given that repackaging by definition disrupts the original packaging hierarchy. See the repackager page.

Third-party logistics providers transport serialized product through the supply chain and must maintain the digital chain of custody alongside the physical shipment. See the 3PL page.

Regulators define requirements, operate national repositories, and enforce compliance. Their role varies substantially by jurisdiction. See the regulators page.

Patients are the ultimate beneficiaries and, increasingly, active participants through patient-facing verification applications. See the patient perspective page.

The coordination across these stakeholders is one of the most complex aspects of pharmaceutical track and trace. No single stakeholder can deliver track and trace alone; the system depends on every link in the chain operating coherently.

08Benefits Beyond Compliance

While compliance is the most immediate driver of track and trace investment, the full benefit picture extends well beyond regulatory requirements. The dedicated benefits page covers this in depth; the high-level summary follows.

The variance between companies in benefit realization is large. Companies that treat track and trace as a compliance ceiling realize the minimum benefit. Companies that treat it as a strategic data foundation realize substantially more. The gap is one of the more consequential competitive dynamics in pharmaceutical supply chain.

09Implementation Realities and Common Challenges

Pharmaceutical track and trace implementations exhibit predictable challenges that recur across companies, geographies, and product types. The dedicated challenges page provides comprehensive treatment; the major patterns include:

Underestimated complexity

Industry post-mortems suggest typical projects exceed original timelines by 30 to 60 percent and budgets by 20 to 40 percent, primarily through accumulated underestimation across multiple workstreams rather than any single dramatic failure.

Master data quality

Inconsistent product codes, incomplete attributes, and multi-country master data divergence consistently emerge as the longest single workstream in implementation projects.

Vendor and system integration

The L1 to L5 architecture involves multiple vendors with different release cycles and integration assumptions, producing friction at every interface.

Regulatory fragmentation

Multinational manufacturers must accommodate distinct technical and operational requirements across every market they serve, with shifting deadlines and evolving requirements adding ongoing complexity.

Exception handling

Serialized lines generate exceptions that did not exist in batch-level operations, requiring dedicated investigation, documentation, and resolution capacity.

EPCIS data exchange

Despite standardization, EPCIS exchange consistently produces operational problems through format variations between trading partners, network reliability issues, and master data alignment failures.

Organizational coordination

Track and trace touches manufacturing, quality, regulatory, IT, supply chain, and commercial functions simultaneously, requiring cross-functional governance that many organizations struggle to establish.

Sustaining compliance after go-live

Implementation is not a project that ends at go-live; ongoing regulatory drift, technology obsolescence, SKU lifecycle management, and trading partner churn require continuous operational attention.

Understanding these patterns in advance is the single most effective way to avoid them. The dedicated implementation roadmap and vendor selection page provide practical guidance.

10The Future of Pharmaceutical Track and Trace

The next decade of pharmaceutical traceability will be shaped by capability expansion on top of the existing serialization architecture rather than architectural replacement. The dedicated future of pharma traceability page covers this in depth; the major trajectories include:

AI-driven analytics

Machine learning systems analyzing serialization event streams will detect counterfeit, diversion, and quality patterns that human analysts and rule-based systems cannot identify.

Blockchain for selected use cases

Distributed ledger systems will continue expanding for specific high-value scenarios involving multiple competing parties, while not displacing centralized serialization repositories.

IoT and continuous monitoring

Sensors integrated with serialization will provide continuous temperature, humidity, location, and shock data tied to specific serialized packs, particularly valuable for biologics and cell and gene therapies.

Patient-facing verification

Smartphone-based authentication will expand substantially, with the most rapid adoption in markets with acute counterfeit problems and high-value therapeutic categories.

EPCIS 2.0 adoption

The transition from EPCIS 1.2 to 2.0 will continue through the late 2020s, enabling cloud-native, API-based integration patterns. See the EPCIS event exchange standard guide for the technical evolution.

Gradual regulatory harmonization

Common technical standards will continue expanding, but national fragmentation will remain the baseline state of the regulatory environment.

Strategic data asset framing

Pharmaceutical companies will increasingly treat serialization data as commercial intelligence rather than compliance overhead, with substantial variance in value extraction between companies.

The fundamental architecture established between 2010 and 2020 will remain the foundation. What evolves is the sophistication of the capabilities built on top of it.